Abbott (NYSE:ABT) announced today that it received FDA clearance and CE mark for its next-generation Ultreon 3.0 software.

Ultreon 3.0 is the first advanced optical coherence tomography (OCT) system in the U.S. and Europe that integrates high resolution coronary plaque images and AI-automated ...

The device joins a portfolio of vascular technologies that generated 9.5% sales growth on a comparable basis in the first ...

Abbott has received both FDA clearance and CE mark for its Ultreon 3.0 software, an AI-powered optical coherence tomography platform for coronary imaging. The system provides real-time guidance during ...